Scott Kathleen D. 4
4 · ARS Pharmaceuticals, Inc. · Filed Aug 21, 2024
Insider Transaction Report
Form 4
Scott Kathleen D.
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-08-20$16.00/sh−12,500$200,000→ 13,199 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-08-20−12,500→ 814,830 totalExercise: $1.50Exp: 2032-02-29→ Common Stock (12,500 underlying) - Exercise/Conversion
Common Stock
2024-08-20$1.50/sh+12,500$18,750→ 25,699 total
Footnotes (3)
- [F1]Includes 2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023 and 1,980 shares acquired under the ESPP on June 28, 2024.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024.
- [F3]Immediately exercisable.